Pharmafile Logo

News and Press Releases

Two Weeks to Go – London Biotechnology Show 2025 Gears Up to Spotlight Industry Pioneers, Disruptive Tech, Emerging Innovators

2 June 2025 -- London, UK -- In just two weeks, the second edition of the London Biotechnology Show (LBS) returns to ExCeL London on 18–19 June, bringing together one...

Category: BioManufacturing, Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: June 2, 2025

London Biotechnology Show
info@londonbiotechshow.com

Chemspec Europe 2025 opens next week: Europe’s top event for fine and speciality chemicals set for strongest edition to date

30 May 2025 -- Koelnmesse, Germany -- From 4–5 June, thousands of industry professionals will gather in Cologne for the 38th edition of Chemspec Europe – the leading marketplace for fine...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: May 30, 2025

Chemspec Europe
Koelnmesse, Germany

Enhancing Clinical Trials for Faster, More Predictable Outcomes with WCG Study Accelerator

May 28, 2025 – CARY, NC – WCG, a global leader in providing solutions that measurably improve and accelerate clinical research, today announced the launch of WCG Study Accelerator, an...

Category: Clinical Trials
Posted: May 29, 2025

WCG Clinical
info@wcgclinical.com
212 Carnegie Center, Suite 301, Princeton, NJ 08540, USA

Attend Europe’s leading vaccine event!

World Vaccine Congress Europe will host 2500+ attendees, 280 speakers, 150 exhibitors and start-ups over the course of 4 days. With a multitude of tracks, the congress will cover everything...

Category: Biotechnology, Other, Pharmaceutical
Posted: May 27, 2025

World Vaccine Congress Europe
tayyab.abbasi@terrapinn.com
Barcelona

Big names, big issues: Chemspec Europe 2025 to deliver strong insights and momentum at a pivotal time for the chemicals industry

22 May 2025 -- Koelnmesse, Germany -- From 4–5 June, the international fine and speciality chemicals industry will gather at Koelnmesse, Germany, for the 38th edition of Chemspec Europe –...

Category: Biotechnology, Other, Pharmaceutical
Posted: May 22, 2025

Chemspec Europe
Koelnmesse, Germany

EuroPCR 2025: Late-Breaking Data Demonstrate Sustained Significantly Lower Event Rates With Elixir Medical’s DynamX Bioadaptor Over Drug-Eluting Stent Through Three Years

Sustained durability of treatment effect with significantly lower TLF rates (2.7% versus 7.2%, p=0.030) with DynamX compared to DES Significantly lower rate of Cardiac Death (0.5% versus 3.2%, p=0.033) with...

Category: Biotechnology, Clinical Trials, Other
Posted: May 21, 2025

Elixir Medical
info@elixirmedical.com
920 N. McCarthy Blvd. Milpitas, CA 95035 U.S.

Heidelberg Pharma to Present Promising New Clinical Data on its Lead ATAC Candidate HDP-101 at EHA 2025

• HDP-101 demonstrated complete response in one female patient from cohort 5• R&D Webinar to be hosted on 17 June 2025. 15 May 2025 -- Ladenburg, Germany -- Heidelberg Pharma...

Category: BioManufacturing, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 15, 2025

Heidelberg Pharma
info@hdpharma.com
Gregor-Mendel-Straße 22 68526 Ladenburg Deutschland

ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences

12 May 2025 -- Leiden, the Netherlands and Massachusetts, US -- ProQR Therapeutics NV (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™...

Category: BioManufacturing, Drug Discovery, Other, Pharmaceutical
Posted: May 15, 2025

ProQR Therapeutics
info@proqr.com
Zernikedreef 9 2333 CK Leiden The Netherlands

Rockville-Based CRO Emmes Groups’ OptymEdge launch the first dedicated ophthalmology clinical trial platform at ARVO

Phase 1 will see new eSource technology launched at event, marking OptymEdge’s evolution into a full-service ophthalmic research partner 14 May 2025 -- Wisconsin, US -- OptymEdge – part of...

Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: May 14, 2025

OptymEdge
11414 West Park Place, Suite 202, Milwaukee, WI 53224, US

Medable Releases New Digital Oncology Trial Offering to Reduce Complexity for Sites, Sponsors, Patients, and Caregivers

Integrated solution with self-service capabilities simplifies trial experience for all 13 May 2025 -- California, US -- Medable Inc., a leading provider of clinical development and eCOA technology, today announced...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 13, 2025

Medable
media@medable.com
525 University Ave Suite A70 Palo Alto, CA 94301

Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025

Analysis of EFX results with AI-based digital pathology underscores the potential value in evaluating histopathology response Data contribute to growing body of support around the anti-fibrotic activity of EFX in...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 10, 2025

Akero Therapeutics
601 Gateway Boulevard, Suite 350 South San Francisco, CA 94080 (650) 487-6488

Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine

Results support potential benefit of efruxifermin (EFX) to elicit fibrosis improvement in patients with compensated cirrhosis (F4 fibrosis) due to MASH 96-week data from SYMMETRY trial presented at EASL Congress 2025...

Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: May 9, 2025

Akero Therapeutics
601 Gateway Boulevard, Suite 350 South San Francisco, CA 94080 (650) 487-6488

iOnctura commences randomized Phase I/II study in non-small cell lung cancer

First patient dosed in study investigating roginolisib + dostarlimab +/- docetaxel in patients with NSCLC who have progressed on prior immunotherapy/chemo Study will evaluate safety of the combination and explore...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 8, 2025

iOnctura
enquiries@ionctura.com
Campus Biotech Innovation Park Avenue Sécheron 15
 1202 Genève
 Switzerland

European Commission approves TREMFYA (guselkumab), the first dual-acting IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn’s disease

TREMFYA (guselkumab) induction therapy administered either intravenously (GALAXI 2 and 3) or subcutaneously (GRAVITI) achieved the co-primary endpoints of clinical remissiona and endoscopic responseb at Week 12 compared to placebo...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 7, 2025

Johnson & Johnson Innovative Medicine
mediaenquiries@its.jnj.com
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

PlaqueTec announces positive early research findings from interim analysis in BIOPATTERN trial

Pre-specified interim analysis reveals differences in protein concentration between systemic blood and blood from diseased coronary arteries Safety and functionality data for the updated Liquid Biopsy System supports continuation of...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 6, 2025

PlaqueTec
info@plaquetec.com
Maia Building (B270) Babraham Research Campus Cambridge CB22 3AT